- Home
- OFS vs CRDF Comparison
OFS vs CRDF Comparison
Compare OFS & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- CRDF
- Stock Information
- Founded
- OFS 2001
- CRDF 1999
- Country
- OFS United States
- CRDF United States
- Employees
- OFS N/A
- CRDF N/A
- Industry
- OFS Finance/Investors Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OFS Finance
- CRDF Health Care
- Exchange
- OFS Nasdaq
- CRDF Nasdaq
- Market Cap
- OFS 115.2M
- CRDF 133.5M
- IPO Year
- OFS 2012
- CRDF N/A
- Fundamental
- Price
- OFS $8.92
- CRDF $4.96
- Analyst Decision
- OFS
- CRDF Strong Buy
- Analyst Count
- OFS 0
- CRDF 3
- Target Price
- OFS N/A
- CRDF $10.33
- AVG Volume (30 Days)
- OFS 61.5K
- CRDF 3.9M
- Earning Date
- OFS 10-31-2024
- CRDF 11-07-2024
- Dividend Yield
- OFS 15.74%
- CRDF N/A
- EPS Growth
- OFS N/A
- CRDF N/A
- EPS
- OFS N/A
- CRDF N/A
- Revenue
- OFS $49,799,000.00
- CRDF $688,000.00
- Revenue This Year
- OFS N/A
- CRDF $23.78
- Revenue Next Year
- OFS N/A
- CRDF N/A
- P/E Ratio
- OFS N/A
- CRDF N/A
- Revenue Growth
- OFS N/A
- CRDF 49.57
- 52 Week Low
- OFS $7.75
- CRDF $1.30
- 52 Week High
- OFS $12.41
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- OFS 71.88
- CRDF 72.82
- Support Level
- OFS $8.08
- CRDF $3.06
- Resistance Level
- OFS $8.72
- CRDF $5.64
- Average True Range (ATR)
- OFS 0.20
- CRDF 0.45
- MACD
- OFS 0.05
- CRDF 0.29
- Stochastic Oscillator
- OFS 90.20
- CRDF 84.32
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").